Table of Contents
Journal of Histology
Volume 2014, Article ID 410952, 9 pages
http://dx.doi.org/10.1155/2014/410952
Research Article

Tissue Expression of Low and High Molecular Weight Cytokeratins in Lung Carcinoma Sections: Its Correlation with Some Clinic-Pathological Features

1Department of Pathology, Manuel Fajardo Teaching Hospital, Zapata and D Street Vedado, Plaza de la Revolución, 10400 Havana, Cuba
2Laboratory of Specific Recognition and Biological Activity, Department of Quality Control, Center of Molecular Immunology, 216 Street and 15 Avenue, Atabey, Playa, P.O. Box 16040, 11600 Havana, Cuba

Received 8 September 2014; Accepted 30 October 2014; Published 17 November 2014

Academic Editor: Francesco Cappello

Copyright © 2014 Charles E. Rengifo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Kaira, N. Oriuchi, N. Sunaga, T. Ishizuka, K. Shimizu, and N. Yamamoto, “Systemic review of PET and biology in lung cancer,” American Journal of Translational Research, vol. 3, no. 4, pp. 383–391, 2011. View at Google Scholar · View at Scopus
  2. C. Gkogkou, K. Frangia, M. W. Saif, R. Trigidou, and K. Syrigos, “Necrosis and apoptotic index as prognostic factors in non-small cell lung carcinoma: a review,” SpringerPlus, vol. 3, no. 1, pp. 1–5, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Giaccone and P. A. Zucali, “Src as a potential therapeutic target in non-small-cell lung cancer,” Annals of Oncology, vol. 19, no. 7, pp. 1219–1223, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Barzi and N. A. Pennell, “Targeting angiogenesis in non-small cell lung cancer: agents in practice and clinical development,” European journal of Clinical and Medical Oncology, vol. 2, no. 1, pp. 31–42, 2010. View at Google Scholar · View at Scopus
  5. T. Berghmans, M. Paesmans, and J. P. Sculier, “Prognostic factors in stage III non-small lung cancer: a review of conventional, metabolic and new biological variables,” Therapeutic Advances in Medical Oncology, vol. 3, no. 3, pp. 127–138, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. R.-P. Perng, C.-Y. Chen, G.-C. Chang et al., “Revisit of 1997 TNM staging system—survival analysis of 1112 lung cancer patients in Taiwan,” Japanese Journal of Clinical Oncology, vol. 37, no. 1, pp. 9–15, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Linder, “Cytokeratin markers come of age,” Tumor Biology, vol. 28, no. 4, pp. 189–195, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Karantza, “Keratins in health and cancer: more than mere epithelial cell markers,” Oncogene, vol. 30, no. 2, pp. 127–138, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Moll, M. Divo, and L. Langbein, “The human keratins: biology and pathology,” Histochemistry and Cell Biology, vol. 129, no. 6, pp. 705–733, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Kummar, M. Fogarasi, A. Canova, A. Mota, and T. Ciesielski, “Cytokeratin 7 and 20 staining for the diagnosis of lung and colorectal adenocarcinoma,” British Journal of Cancer, vol. 86, no. 12, pp. 1884–1887, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Blanco, C. E. Rengifo, M. Cedeño, M. Frómeta, E. Rengifo, and A. Carr, “Immunoreactivity of the 14F7 Mab (Raised against N-Glycolyl GM3 ganglioside) as a positive prognostic factor in non-small-cell lung cancer,” Pathology Research International, vol. 2012, Article ID 235418, 12 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. C. E. Rengifo, R. Blanco, D. Blanco, M. Cedeño, M. Frómeta, and E. Rengifo, “Immunohistochemical characterization of three monoclonal antibodies raised against the epidermal growth factor and its receptor in non-small cell lung cancer: their potential use in the selection of patients for immunotherapy,” Journal of Biomarkers, vol. 2013, Article ID 627845, 9 pages, 2013. View at Publisher · View at Google Scholar
  13. H. Kitamura, T. Yazawa, K. Okudela, H. Shimoyamada, and H. Sato, “Molecular and genetic pathogenesis of lung cancer: differences between small-cell and non-small-cell carcinomas,” The Open Pathology Journal, vol. 2, pp. 106–114, 2008. View at Google Scholar
  14. W. Travis, S. Nicholson, F. R. Hirsch et al., “Small cell carcinoma,” in Tumours of the Lung. Tumours of the Lung, Pleura, Thymus and Heart. World Health Organization Classification of Tumours, W. D. Travis, E. Brambilla, H. K. Mueller-Hermelink, and C. C. Harris, Eds., Pathology & Genetics, pp. 31–34, IARC Press, Lyon, France, 2004. View at Google Scholar
  15. X. Jin, Z. Wang, L. Qiu et al., “Potential biomarkers involving IKK/RelA signal in early stage non-small cell lung cancer,” Cancer Science, vol. 99, no. 3, pp. 582–589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Qiu, H. Yang, H. Chen et al., “Detection of CEA mRNA, p53 and AE1/AE3 in haematoxylin-eosin-negative lymph nodes of early-stage non-small cell lung cancer may improve veracity of N staging and indicate prognosis,” Japanese Journal of Clinical Oncology, vol. 40, no. 2, Article ID hyp144, pp. 146–152, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Blanco, C. E. Rengifo, M. Cedeño, M. Frómeta, and E. Rengifo, “Flow cytometric measurement of aneuploid DNA content correlates with high S-phase fraction and poor prognosis in patients with non-small-cell lung cancer,” ISRN Biomarkers, vol. 2013, Article ID 354123, 8 pages, 2013. View at Publisher · View at Google Scholar
  18. G. Buccheri and D. Ferrigno, “Lung tumor markers of cytokeratin origin: an overview,” Lung Cancer, vol. 34, supplement 2, pp. S65–S69, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. G. B. Jens, S. N. Hubertus, G. Bernhard, H. Achim, and J. S. Norbert, “CK-19 serum analysis in patients with esophageal cancer,” Clinical Cancer Research, vol. 6, pp. 249–252, 2000. View at Google Scholar
  20. J. Fujita, Y. Ohtsuki, S. Bandoh et al., “Elevation of cytokeratin 19 fragment (CYFRA 21-1) in serum of patients with radiation pneumonitis: possible marker of epithelial cell damage,” Respiratory Medicine, vol. 98, no. 4, pp. 294–300, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Rastel, A. Ramaioli, F. Cornillie, and B. Thirion, “CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation,” European Journal of Cancer, vol. 30, no. 5, pp. 601–606, 1994. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Barbareschi, C. Cantaloni, V. D. Vescovo et al., “Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis,” American Journal of Clinical Pathology, vol. 136, no. 5, pp. 773–782, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Johansson, “Histopathologic classification of lung cancer: relevance of cytokeratin and TTF-1 immunophenotyping,” Annals of Diagnostic Pathology, vol. 8, no. 5, pp. 259–267, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. J. N. Kitinya, M. Kingo, and K. Tanaka, “Expression of cytokeratin and neuron-specific enolase in small cell carcinomas of the lung,” Histology and Histopathology, vol. 2, no. 4, pp. 333–343, 1987. View at Google Scholar · View at Scopus
  25. W. D. Travis, “Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas,” Modern Pathology, vol. 25, pp. 18–30, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Chu, E. Wu, and L. M. Weiss, “Cytokeratin 7 and Cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases,” Modern Pathology, vol. 13, no. 9, pp. 962–972, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Bobos, P. Hytiroglou, I. Kostopoulos, G. Karkavelas, and C. S. Papadimitriou, “Immunohistochemical distinction between Merkel cell carcinoma and small cell carcinoma of the lung,” American Journal of Dermatopathology, vol. 28, no. 2, pp. 99–104, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Zhang, J. Liu, P. T. Cagle, T. C. Allen, A. C. Laga, and D. S. Zander, “Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach,” Modern Pathology, vol. 18, no. 1, pp. 111–118, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. C. W. Michael, “Lung Carcinoma,” in Serous Effusions, B. Davidson, P. Firat, and C. W. Michael, Eds., pp. 27–45, Springer, London, UK, 2012. View at Google Scholar
  30. N. G. Ordóñez, “Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma: The M.D. Anderson experience and a critical review of the literature,” American Journal of Clinical Pathology, vol. 109, no. 1, pp. 85–89, 1998. View at Google Scholar · View at Scopus
  31. I. N. Soomro, R. Oliveira, J. Ronan, Z. R. Chaudry, and J. Johnson, “Expression of mesothelial markers in malignant mesotheliomas: an immunohistochemical evaluation of 173 cases,” Journal of the Pakistan Medical Association, vol. 55, no. 5, pp. 205–209, 2005. View at Google Scholar · View at Scopus
  32. Y. Fukunaga, S. Bandoh, J. Fujita et al., “Expression of cytokeratin 8 in lung cancer cell lines and measurement of serum cytokeratin 8 in lung cancer patients,” Lung Cancer, vol. 38, no. 1, pp. 31–38, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Cohen, A. Guber, A. Siegal et al., “The prognostic application of cytokeratin typing of non small cell lung carcinoma,” Cancer, vol. 79, pp. 468–473, 1997. View at Google Scholar
  34. M. Kosacka and R. Jankowska, “The prognostic value of cytokeratin 19 expression in non-small cell lung cancer,” Pneumonologia i Alergologia Polska, vol. 75, no. 4, pp. 317–323, 2007. View at Google Scholar · View at Scopus
  35. Y. Chen, T. Cui, L. Yang et al., “The diagnostic value of cytokeratin 5/6, 14, 17, and 18 expression in human non-small cell lung cancer,” Oncology, vol. 80, pp. 333–340, 2011. View at Google Scholar
  36. M. Ono, H. Kijima, H. Seino, K. Hakamada, and Y. Igarashi, “Expression of cytokeratin 34βE12 is a good indicator of tumor progression in esophageal squamous cell carcinoma,” Biomedical Research, vol. 33, no. 3, pp. 183–189, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. D. Ramos, S. Navarro, R. Villamón, M. Gil-Salom, and A. Llombart-Bosch, “Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder,” Cancer, vol. 97, no. 8, pp. 1876–1883, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Mehta, R. K. Jain, N. Sneige, S. Badve, and E. Resetkova, “Expression of high-molecular-weight cytokeratin (34βE12) is an independent predictor of disease-free survival in patients with triple-negative tumours of the breast,” Journal of Clinical Pathology, vol. 63, no. 8, pp. 744–747, 2010. View at Publisher · View at Google Scholar · View at Scopus